A type of cancer of lymph-nodes
POPULARITY
35 episodes with Non-Hodgkin lymphoma
33 episodes with Non-Hodgkin lymphoma
19 episodes with Non-Hodgkin lymphoma
33 episodes with Non-Hodgkin lymphoma
13 episodes with Non-Hodgkin lymphoma
13 episodes with Non-Hodgkin lymphoma
15 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
5 episodes with Non-Hodgkin lymphoma
4 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
4 episodes with Non-Hodgkin lymphoma
33 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
15 episodes with Non-Hodgkin lymphoma
13 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
6 episodes with Non-Hodgkin lymphoma
3 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
2 episodes with Non-Hodgkin lymphoma
This week on the Wednesday Dose of Dopey! Dave kicks off an intensely emotional episode amid personal chaos—grieving Linda's dad's death, a bizarre Verizon outage conspiracy vibe, a $1,100 car repair scam, and a half-hearted gratitude meditation to stay grounded. He reads glowing listener comments on the recent Sid Vicious/Ned Van Zandt heroin epic, plugs stickers for Spotify/iTunes reviews, and shares a powerful email from Sarah E. about her ongoing brutal struggle with 7-OH (7-hydroxymitragynine) dependence after accidents and kratom escalation, highlighting deception, severe withdrawals, and the "master of deception" label despite a strong sober community.The core is a raw, heartfelt interview with returning guest Erin Khar (author of Strung Out, unlicensed advice columnist), who opens up about her recent diagnosis of small lymphocytic lymphoma (SLL) / chronic lymphocytic leukemia (CLL)—a slow-growing, incurable non-Hodgkin B-cell lymphoma discovered via routine mammogram/biopsy around Labor Day. Erin details the terrifying pathology call, symptoms (years of unexplained fatigue, anemia, frequent illnesses), watch-and-wait monitoring (no treatment yet until lymphocyte count rises), good-news/bad-news aspects (no chemo likely, keeps her hair, many live normal lifespans especially younger diagnoses like her at 52), and how curiosity over fear helps her cope.They explore parallels to addiction/recovery (one day at a time, sitting on hands during suicidal moments, grief + gratitude coexisting), family impact (kids' anxiety, protecting emotions), quality over quantity of life, and Erin's Substack reveal for connection. Ends with an Ask Erin advice segment, Johnny Thunders love ("Can't Put Your Arms Around a Memory"), and Trinity's cover of "Wanna Be Good So Bad". ALL THAT AND MORE MORE MORE! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
Jean Koff, MD, MSc Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it's an umbrella term for multiple subtypes, and what today's treatments and tomorrow's innovations could mean for you. From understanding subtypes and staging to exploring options like watchful waiting, chemotherapy, and cutting-edge immunotherapies, we cover what matters most: knowledge, clarity, and hope. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Non-Hodgkin lymphoma The Lymphoma Guide Lugano staging system Immunotherapy fact sheet CAR T-cell therapy Allogeneic stem cell transplantation Clinical Trial Support Center Online NHL Chat Additional Blood Cancer United Support Resources: Free Nutrition Consultations Information Specialists Financial support Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Supported by AbbVie Inc. and Genentech, A Member of the Roche Group.The post The Big Picture on Non-Hodgkin Lymphoma: Treatments, Trends, and Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.
Featuring perspectives from Dr Jeremy S Abramson and Dr Loretta J Nastoupil, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (0:00) Potential Treatment Benefits of CAR T-Cell Therapy (13:31) Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (28:13) Finding Information About CAR T-Cell Therapy; Clinical Trials (36:28) Financial Issues; Risk of Infection (42:02) Coping with Anxiety; Healing and Moving On (53:27) CME information and select publications
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.
Dave Coulier annouced that he's battling tongue cancer just months after beating Non-Hodgkin Lymphoma. Luckily, it's very treatable. Miley Cyrus is engaged to Maxx Morando!See omnystudio.com/listener for privacy information.
In this episode, we review the high-yield topic of Hodgkin vs. Non-Hodgkin Lymphoma from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics: Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.
Featuring perspectives from Dr Carla Casulo and Dr Brad S Kahl: Introduction (0:00) Faculty Data and Case Presentation — Dr Kahl (6:38) Faculty Data and Case Presentation — Dr Casulo (25:38) CME information and select publications
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.
Dr. Morse Q&A - Non-Hodgkin Lymphoma - Fungus - Asthma -Tongue Cancer - Burning Feet Syndrome and More #800 00:00:00 - Intro 00:00:39 - Non-Hodgkin Lymphoma 00:33:06 - Pelvic and Abdominal Issues 00:56:40 - Fungus - Asthma - Psoriasis - Candida 01:21:22 - Tongue Cancer - Burning Feet Syndrome 00:00:39 - Non-Hodgkin Lymphoma In the past I had chemo, as well as radiation. 00:33:06 - Pelvic and Abdominal Issues Worse with standing, coughing and bowel movements. 00:56:40 - Fungus - Asthma - Psoriasis - Candida My husband has really bad nail fungus on almost all nails and toes. 01:21:22 - Tongue Cancer - Burning Feet Syndrome I am facing tongue cancer treatment from the medical system.
Giulia Zamagni joins Claudia Schaefer to discuss her recent Series of 4 papers from the Italian Global Burden of Disease collaborators providing the disease burden estimates and temporal trends for leukemia, multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma in Italy.Click here to read the full text in this series: paper 1; paper 2; paper 3; paper 4 Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamabMonitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamigPresenters: Dr Christopher Flowers Division Head, Division of Cancer MedicineChair, Professor, Department of Lymphoma/MyelomaJohn Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer MedicineMD Anderson Cancer CenterHouston, TexasDr John AllanAssociate Professor of Clinical MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by Regeneron Pharmaceuticals, Inc.
Laurie Adami seemed to have it all. She was the president of her company, at age 40, she had just had a son and still found time to lead an active lifestyle. However, in 2003, her health took a turn for the worse. She felt a lump in her abdomen, experienced frequent, lengthy sinus infections and chronic fatigue. All this led to a diagnosis of Stage IV Follicular Non-Hodgkin Lymphoma. After six unsuccessful treatment regimens, she achieved complete remission on the seventh try, completing a battle that ran twelve years. When Laurie initially brought her symptoms to the attention of her family doctor, they were dismissed as, at worst, a hernia, and exhaustion due to her demanding schedule; but Laurie insisted there was nothing ordinary about her symptoms and changed doctors. She saw a hernia specialist who ordered a CT scan, which revealed a mass the size of a small watermelon on her abdomen. After a biopsy, Laurie learned she had Stage IV Follicular Non-Hodgkin Lymphoma. At that time, she had no idea of the difficulty and length of the journey awaiting her. The first of six treatments that failed to overcome her diagnosis was in 2006 and called R-CHOP. It was a mix of Rituxan plus Cytoxan, Adriamyacin and Prednisone. Next in 2008 was a clinical trial of Rituxan, along with an HDAC inhibitor. In 2010, Laurie tried Bendamustin, a medication popular in Eastern Europe. When that didn't work, later in the year, she went with Bexxar Radioimmunotherapy. Of the first six regimens, Laurie had the most success with a pi3 kinase inhibitor called Zydelig. For five and a half years ending in 2016, it shrunk the tumor without eliminating it. The tumor returned and for six months ending in September 2017, she tried infusions of Gazvya. On July 16, 2018, her tumor was still around, but Laurie qualified for a Phase II clinical trial of Yescarta CAR-T therapy. Some 29 days later, her lymphoma specialist informed her she was in full remission. Laurie Adami has resumed an active lifestyle, and does plenty of traveling, most of it to public speaking engagements, as she serves as an advocate for the Leukemia & Lymphoma Society. Additional Resources: Support Group: The Leukemia & Lymphoma Society https://www.lls.org
In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI
Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here.
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications
Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics: Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00) Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09) First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03) Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31) Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59) NCPD information and select publications
Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.
Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.
Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 1: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies in Various Non-Hodgkin Lymphoma (NHL) Subtypes — Brian T Hill, MD, PhD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 2: Other Available and Emerging Novel Therapies for NHL — Stephen M Ansell, MD, PhD CME information and select publications
Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.
Featuring an interview with Dr Jennifer Crombie, including the following topics: Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00) Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40) Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52) Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46) Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06) Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19) CME information and select publications
Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.
Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications
Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma. CME information and select publications here.
Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications
Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.
Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications
In this episode of The Aging Well Podcast, Dr. Jeff Armstrong and Corbin Bruton are joined by Chris Vogelsang. Chris shares his inspiring journey through cancer diagnosis, treatment, and recovery. Diagnosed with Non-Hodgkin Lymphoma in 2008, Chris discusses the emotional impact of his diagnosis, the challenges he faced, and the importance of maintaining a positive attitude. He explains the innovative CAR-T therapy he underwent at Roswell Park Comprehensive Cancer Center in Buffalo, NY and reflects on the changes in his life post-treatment, emphasizing the value of family, relationships, and living in the moment. Chris offers advice to others battling cancer, highlighting the advancements in medical treatments and the importance of hope and support.https://www.roswellpark.org/
Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SOHO2024/CARTCell/Video).
Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support patients with non-Hodgkin lymphoma access treatment.
Four year Idaho HealingStrong Group Leader, Benjamin Canales, shares his inspiring journey from his New York roots to overcoming cancer to now leading a free support group based in holistic health. In 2016, Ben received his cancer diagnosis, and described the initial symptoms. Ben also mentions the spiritual journey that emerged as an integral part of his healing process. Learn from Ben's insights as he highlights the deep impact of faith, community, and holistic healing in his path to recovery.You will hear the reality of seeking alternative cancer treatments and the emotional roller coaster that accompanies it in his story such as the interactions with different oncologists. Discussed is the importance in understanding cancer as a symptom of deeper health issues and prioritizing nutrition. Through Ben's involvement with HealingStrong, he connects with others seeking a community and most often, alternative paths, and support from others navigating similar fears and/or challenges.Celebrate the growth of the HealingStrong Group in Idaho, and gain insight into how community and shared resources and experiences can positively impact one's healing journey. This episode is a testament to the strength found in rebuilding the body, renewing the soul, and refreshing the spirit, offering hope and encouragement for anyone on their own path to health and healing. Be inspired to take charge of your health journey and discover the resources available through the HealingStrong organization for a more holistic approach to wellness.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program
Firefighter, cancer survivor and advocate Nick Howe shares his experiences of surviving cancer with an experimental treatment, only a few years later to require a new heart during which time a spinal stroke left him paralyzed from the waist down. Howe talks about a desire to dedicate his life in service to others initially taking the form of being a firefighter, as well as a spouse and father, but which now has assumed a new shape and vitality of purpose.Nick and Rachel Howe met initially in 2005 and later married. Nick worked as firefighter and Rachel as a teacher. In 2016, the onset of severe health issues for Nick was diagnosed as Non-Hodgkin Lymphoma that chemotherapy, immunotherapy and an autologous stem-cell transplant failed to treat. To save his life, he underwent a highly experimental therapy called CAR T-cell therapy and he has been in remission since. After welcoming their two children, in the summer of 2022, Nick experienced more illness and received a heart transplant. A few weeks later, with his new heart failing, Nick was placed in a medically induced coma during which time he had a spinal stroke that has left him paralyzed from the waist down. Nick's dedication to supporting others now includes serving as the Nebraska State Director for the Firefighter Cancer Support Network and as an ambassador for LLS and Lymphoma Research Foundation. Nick, his wife Rachel, and their two kids live in Omaha, Nebraska.
Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:10) Updates in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr S Smith (33:32) CME information and select publications
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024).
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.
In this episode, we talk with Dr. Hassan Alkhateeb, a hematologist from the Mayo Clinic Transplant Center, about CAR T-cell therapy. Dr. Alkhateeb walks us through the basics of this groundbreaking immunotherapy and how it has evolved as a treatment option for various cancers. CAR T-cell therapy involves collecting a patient's T cells and re-engineering them in the lab to target and destroy cancer cells. This therapy has shown promise in treating blood cancers like B-cell acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, multiple myeloma, and even solid tumors like synovial sarcoma.The origins of CAR T therapy date back to 2011, with the first FDA-approved product arriving in 2017. Since then, the therapy has rapidly expanded to treat more conditions. Dr. Alkhateeb explains that while CAR T is often seen as a last-resort treatment, especially in cases where patients have not responded to other therapies, early referral to CAR T specialists is becoming more common. This shift can improve outcomes, as earlier intervention allows for better preparation and potentially more effective treatment.He outlines the evaluation process for CAR T therapy, which is similar to that for bone marrow transplants but focuses on assessing the patient's overall health and suitability for cell collection rather than matching a donor. The cells are then modified in a lab, a process that typically takes two to three weeks. Dr. Alkhateeb notes that manufacturing failures are rare, affecting about 3% of cases.Post-treatment, patients must be monitored closely for side effects such as drops in blood counts, risk of infections, and specific complications like cytokine release syndrome (CRS) and neurotoxicity. These side effects can be severe but are generally manageable with the right care. Caregivers play a crucial role in this process, especially since patients need to stay near the treatment center for an extended period.Dr. Alkhateeb also shares inspiring success stories, including one patient with a particularly challenging form of leukemia who achieved remission and is now back to living a normal life. This highlights the life-saving potential of CAR T therapy and its impact on patients who otherwise have limited options.As we conclude, Dr. Alkhateeb emphasizes the importance of early referrals to specialized centers with experience in CAR T therapy. He expresses optimism about the future of cancer treatment, noting that advancements in this field are providing new hope for patients and their families. We are grateful for his insights and encourage listeners to stay informed about emerging therapies like CAR T, which are transforming the landscape of cancer care.Links:Mayo Clinic Transplant Center: https://www.mayoclinic.org/departments-centers/transplant-centerCAR T-Cell Therapy Information: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/car-t-cellFDA Approval Information on CAR T Therapies: https://www.fda.gov/news-events/press-announcements/fda-approves-first-car-t-cell-therapyThis season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/
Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15) CME information and select publications
The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.
The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).
In this episode, we review the high-yield topic of Hodgkin vs Non-Hodgkin Lymphoma from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications
© 2020-2026 Ivy Podcast Discovery LLC
